FLAK 17 CV

General Information


DRACP ID  DRACP01736

Peptide Name   FLAK 17 CV

Sequence  VAKALAKALLKALKAL

Sequence Length  16

UniProt ID  Not available

PubChem CID  Not available

Origin  FLAK peptides

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
BMKC Skin carcinoma Carcinoma Not available MTT assay 24 h Patent

Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antibacterial; Antifungal



Structure Information


PDB ID  Not available

Predicted Structure  DRACP01736

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Amidation

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C77H144N20O17

Absent amino acids  CDEFGHIMNPQRSTWY

Common amino acids  A

Mass  188989

Pl  11.28

Basic residues  4

Acidic residues  0

Hydrophobic residues  12

Net charge  4

Boman Index  1730

Hydrophobicity  115

Aliphatic Index  177.5

Half Life 
  Mammalian: 30 hour
  Yeast: >20 hour
  E.coli: >10 hour

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  0

Amino acid distribution



Literature Information


Literature 1

Pubmed ID Not available

Title  Not available

Doi Not available

Year  Not available

Patent

Patent ID US2005/0209157A1

Patent Title  Short bioactive peptides and methods for their use

Other Iinformation  Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status: Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.